BioMarin Pharmaceutical Inc. announced that data from its ongoing Phase 1/2 trial for BMN-673 for genetically-defined cancers will be released at the American Society of Clinical Oncology (ASCO) meeting in Chicago on June 3, 2013. At ASCO, the company will present data from 18 gBRCA breast cancer patients, including six patients from the dose escalation cohort at doses ranging from 25 ug to 1100 ug and twelve patients from the dose expansion cohort at a dose of 1.0 mg. Data will also be presented from 28 gBRCA ovarian cancer patients, including 17 patients from the dose escalation cohort and 11 patients from the dose expansion cohort.

BioMarin Pharmaceutical Inc. Presents at UBS Global Healthcare Conference, May-21-2013 09:00 AM. Venue: Sheraton New York Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: Daniel K. Spiegelman, Chief Financial Officer and Executive Vice President.

BioMarin Pharmaceutical Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company reported GAAP net loss of $39.8 million or $0.31 per basic and diluted share compared to GAAP net loss of $24.0 million or $0.21 per basic and diluted share for the first quarter of 2012. Non-GAAP adjusted EBITDA was a loss of $8.0 million compared to non-GAAP adjusted EBITDA loss of $0.1 million for the first quarter of 2012. The increased GAAP net loss and the increased non-GAAP adjusted EBITDA loss for the first quarter of 2013 compared to the first quarter of 2012 was primarily due to increased net product revenue offset by a larger increase in research and development expenses. Loss from operations was $32.92 million compared to $21.87 million reported a year ago. Loss before taxes was $44.52 million compared to $24.01 million reported a year ago. Total revenues were $127.93 million compared to $116.65 million reported a year ago. LBITDA was $34.8 million compared to $6.0 million reported a year ago. The company reaffirmed earnings guidance for the year ending December 31, 2013. For the year, the company expects total revenue of $530 million to $555 million, research and development expense of $340 million to $380 million, GAAP net loss of $195 million to $170 million, non-GAAP adjusted LBITDA of $75 million to $50 million, interest expense, net, of $0.7 million, depreciation expense of $25.0 million, amortization expense of $10.5 million and LBITDA of $173.4 million to $148.4 million.